When was CF PharmTech founded?

CF PharmTech was founded in 2007 and raised its 1st funding round 10 years after it was founded.

Where is CF PharmTech located?

CF PharmTech is headquartered in Suzhou, China.

Is CF PharmTech a funded company?

CF PharmTech is a funded company, having raised a total of $206M across 3 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Aug 27, 2017.

When was the latest funding round of CF PharmTech?

CF PharmTech's latest funding was a $***** Series F round on Jul 02, 2020, with participation from 6 investors. Its primary sector is Life Sciences Platforms and Tools. In China, the Life Sciences Platforms and Tools sector has seen $61.9M in funding in 2026 to date.

Where does CF PharmTech rank among its competitors?

CF PharmTech ranks 31st amongst 1955 active competitors, of which 451 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of CF PharmTech?

CF PharmTech's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

CF PharmTech - 2026 Company Profile, Team, Funding & Competitors

Company Details

CF PharmTech is a Chinese, commercial-stage, specialty Respiratory-focused drug-delivery development company, and CDMO. The company develops formulations and devices required for the metered-dose inhaler, inhalation powder, nasal spray, and blow-fill-seal products. The disease areas focused on are Rhinitis, Asthma, and COPD, and also other respiratory diseases. The company develops new formulations for existing and new substances, new delivery systems for existing and new APIs, and working with independent research teams to develop new products.

Website: cfpharmtech.com
Email ID: *****@cfpharmtech.com
Phone Number: +86 **********

Key Metrics

Founded Year

2007

Location

Suzhou, China

Stage

Public

Total Funding

$206M in 3 rounds

Latest Funding Round

Series F, Jul 02, 2020, $*****

Investors

New Alliance Capital & 22 more

Ranked

31^st among 1955 active competitors

Similar Companies

Antheia & 2663 more

Exit Details

Public

View CF PharmTech's full profile

CF PharmTech got listed on Oct 08, 2025.

Click here to take a look at CF PharmTech's IPO in detail

CF PharmTech has raised a total funding of $206M over 3 rounds. Its first funding round was on Aug 27, 2017. Its latest funding round was a Series F round on Jul 02, 2020 for $*****. 6 investors participated in its latest round. CF PharmTech has 23 institutional investors.

Here is the list of recent funding rounds of CF PharmTech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 02, 2020	5978052	Series F	9984060	6332203	1135427	1711083
Jan 02, 2020	6461177	Series E	6420392	2392734	3576764	Junxin Capital & 5 more
Aug 27, 2017	2199423	Series D	9455267	8420142	SDIC Innovation	Gantry Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of CF PharmTech's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CF PharmTech include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of CF PharmTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Sequoia Capital & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
8th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, F-Prime Capital & 22 others	61/100
31st	CF PharmTech 2007, Suzhou (China), Public	Chinese, commercial-stage, specialty Respiratory-focused drug-delivery development company and CDMO	$206M	CCB International, SDIC Innovation & 21 others	57/100